Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PI3K/AKT/mTOR pathway is a frequently altered signalling pathway in endometrial cancer.
|
31588998 |
2019 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, we identified that CCL18 derived from TAMs upregulated KIF5B expression to promote EMT via activating the PI3K/AKT/mTOR signaling pathway in endometrial cancer.
|
30779215 |
2019 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Downregulation of PDCD4 induced by progesterone is mediated by the PI3K/AKT signaling pathway in human endometrial cancer cells.
|
31233196 |
2019 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although molecular characterization has been reported to customize therapeutic strategies and thereby improve therapeutic outcomes in EC, none of the targeted agents investigated (antiangiogenic and mTOR/PI3K pathway inhibitor agents) have resulted in a change in clinical practice in HR-EC.
|
31176047 |
2019 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
The PI3K/AKT/mTOR pathway is frequently overactivated in endometrial cancer (EC).
|
30853360 |
2019 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer.
|
30574817 |
2019 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer.
|
30569174 |
2019 |
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Subsequently, Western blotting was used to detect the expression level of PI3K/AKT in EC.
|
31486482 |
2019 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
More recently, molecular analysis of endometrial cancer revealed phosphorylation-dependent oncogenic signalling in the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways to be most frequently altered in type II ECs.
|
30104481 |
2018 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
The HGF/Met-MAPK/PI3K pathway in endometrial cancer is activated by HGF in an autocrine manner.
|
29854314 |
2018 |
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Somatic loss of phosphatase and tensin homolog (PTEN), a tumor suppressor that counteracts phosphoinositide 3-kinase (PI3K) activity, is one of the most common genetic aberrations in endometrioid endometrial cancer.
|
28945226 |
2018 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
We attempt to investigate the effect of metformin on Ki-67, PI3K, p-AKT, p-S6K1, and p-4EBP1 staining in human endometrial cancer by immunohistochemical staining.
|
29182407 |
2018 |
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Taken together, our results showed that the formulation of BSYX had antitumor effect on endometrial cancer in vivo and in vitro and was related with FSH/PI3K/AKT/Gankyrin/HIF-<i>α</i>/cyclinD1 transduction pathway.
|
30402135 |
2018 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, genetic studies evaluated the effect of inflammatory cytokines secreted by visceral adipocytes in the modulation of angiogenesis and signaling pathways such as PI3K/AKT/mTOR, that result altered in the pathogenesis of EC.
|
30338797 |
2018 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
13 EC cell lines were profiled for their PI3K pathway and KRAS mutational and PTEN protein status and treated with one MEK- and two PI3K- targeted inhibitors alone and in combination.
|
29426295 |
2018 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
We assessed the sensitivity of endometrial cancer cell lines to PARP inhibitors (olaparib and BMN-673) and a PI3K inhibitor (BKM-120), alone or in combination, in the context of their PTEN mutation status.
|
28886696 |
2017 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endometrial cancers display hyperactivation of the MAPK and PI3K pathways, the result of somatic aberrations in genes such as <i>FGFR2, KRAS, PTEN, PIK3CA</i>, and <i>PIK3R1</i> The FGFR2 and PI3K pathways, have emerged as potential therapeutic targets in endometrial cancer.
|
28119489 |
2017 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings suggest that PIK3CB/p110β contributes to some of the pleiotropic functions of PI3K in endometrial cancer, particularly in the early steps by contributing to cell proliferation.
|
28002804 |
2017 |
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Previous studies have shown that activation of the PI3K-protein kinase B (Akt) signaling pathway has important effects on insulin resistance and endometrial cancer.
|
27613818 |
2017 |
Malignant neoplasm of endometrium
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Strikingly, coordinate knockdown of YAP and TAZ, mimicking activation of the HIPPO pathway, markedly decreased both constitutive and growth factor-induced PI3K pathway activation by decreasing levels of the GAB2 linker molecule in endometrial cancer lines.
|
28202507 |
2017 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mutations of the phosphoinositide-3-kinase (PI3K) catalytic subunit alpha gene (PIK3CA) are frequent in endometrial cancer.
|
28860563 |
2017 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-101 reduces cell proliferation and invasion and enhances apoptosis in endometrial cancer via regulating PI3K/Akt/mTOR.
|
29081412 |
2017 |
Malignant neoplasm of endometrium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Identification of an endometrial cancer risk allele within a member of the PI3K/AKT signaling pathway, more commonly activated in tumors by somatic alterations, raises the possibility that well tolerated inhibitors targeting this pathway could be candidates for evaluation as chemopreventive agents in individuals at high risk of developing endometrial cancer.
|
27259051 |
2016 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of PI3K/Akt signaling reversed the enhanced cell growth in Nedd4-overexpressing endometrial cancer cells.
|
26193427 |
2015 |
Malignant neoplasm of endometrium
|
0.100 |
Biomarker
|
disease |
BEFREE |
The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endometrial cancer (EC).
|
25624430 |
2015 |